Healthcare is one of the sectors where a federal rule change lands directly on a company's income statement, and a recent screen from Simply Wall Street makes the arithmetic plain. It flags three firms whose cash flows hinge on US policy changes: BrightSpring Health Services, Clover Health Investments and agilon health. Each earns nearly all of its revenue inside the United States, and each sits on a different federal payment rail.
The scale gap is the first thing the data shows. BrightSpring generated about US$14.4 billion in revenue, split between roughly US$12.7 billion from Pharmacy Solutions and US$1.7 billion from Provider Services, with a market value near US$13 billion. Clover earns about US$2.5 billion from its insurance segment and carries a market value near US$2.5 billion. agilon manages about US$5.9 billion in Medicare-centric arrangements against a market value near US$1.5 billion. Same policy exposure, three very different revenue-to-value profiles.
This is analysis of what the screen reveals about where policy risk concentrates. It is not investment advice, and the figures below are the company metrics as reported in the Simply Wall Street article.
What does BrightSpring actually sell to the government?
BrightSpring delivers home and community-based care and pharmacy services to government-backed and insured patients, rather than running a consumer-facing retail model. Per the screen, approximately 80% of its revenue comes from specialty and institutional pharmacy services. That includes infusion therapies delivered at home, long-term care pharmacy services, and specialty drug distribution for chronic and rare disease patients.
The policy lever here is reimbursement. Pharmacy reimbursement rates are set by a mix of federal program rules and payer contracts, and a single policy-driven reimbursement lever moving faster than the market expects could reshape the company's margins. The screen's framing is worth noting: it does not claim the lever will move, only that the company's risk-reward profile depends on where it lands.
Why does Medicare Advantage matter so much to Clover?
Clover runs Medicare Advantage plans, the privately administered alternative to traditional Medicare, plus a physician software platform. Both tie directly into US Medicare funding and benefit design. Its model is built around policy-linked enrollment and benefits rather than discretionary consumer spending, which means the federal government effectively sets the size of its addressable market year after year.
The company's stated case, as quoted in the screen, is that its Clover Assistant platform positions it to benefit from the industry's shift toward technology adoption and data-driven, value-based care, supporting lower medical costs and higher medical margins. The open question the screen raises is the split: if a small policy adjustment changes how technology-driven care savings are shared between Clover, providers, and Medicare, the margin profile changes with it. The savings exist; who keeps them is a policy decision.
How does agilon's model depend on federal reimbursement rules?
agilon health runs a senior-focused primary care platform built around value-based contracts, which pay providers for outcomes rather than the traditional fee-for-service volume of visits. It manages senior care for primary care physicians through a per-member-per-month platform, earning about US$5.9 billion from Medicare-centric arrangements in the United States.
The screen quotes the company's growth argument directly: the accelerating growth of the senior population, especially among the 80+ age group, fuels multi-year demand, and rapid adoption of Medicare Advantage plans continues to favor the business. But the same mechanism that drives growth transmits risk. Regulatory tweaks to Medicare reimbursement flow straight through the per-member-per-month economics, changing how much the company keeps on each enrolled senior.
What does the comparison show about policy exposure?
Set side by side, the three companies illustrate three distinct transmission channels for federal healthcare policy:
- Reimbursement rates — BrightSpring's pharmacy economics move with what payers reimburse for specialty and institutional drugs.
- Benefit design and enrollment — Clover's market size is set by Medicare Advantage funding and benefit rules.
- Value-based contract mechanics — agilon's per-member economics depend on how federal rules score risk and outcomes.
The pattern generalizes. A business earning US$14.4 billion almost entirely from US government-backed and insured patients is not exposed to healthcare policy in the abstract. It is exposed to specific levers, on specific schedules, set by specific agencies and committees.
Where does the uncertainty actually sit?
The screen's own context is the 2026 election cycle, with heavy political spending, polling that barely moves, and policy risk that keeps grinding higher. That framing matters because healthcare policy rarely turns on campaign drama alone. It turns on rulemaking, scoring and benefit design — the machinery readers can follow in How a Federal Agency Writes a Rule and in What a CBO Score Decides for a Bill. A reimbursement change that looks sudden in a stock chart usually took months of proposed rules and cost estimates to arrive.
The strongest counterargument to the screen's thesis is that policy exposure cuts both ways and is hard to time. The article itself concedes the point, noting that its three highlighted stocks are a sample set from a larger screen of 15 companies spanning renewables, healthcare, and regulated utilities, and that fresh policy stories often move first and fast, then slow once the crowd notices. That is a fair description of the risk: by the time a policy link is obvious enough to publish, part of the repricing may already have happened.
The answer is that the exposure is real but specific. Investors and analysts tracking these firms do not need to predict elections. They need to read the reimbursement rule, the benefit design notice, and the contract mechanics — the same documents that determine what a Medicare change means for how Medicare drug negotiation works more broadly.
What does this change?
The evidence here establishes one thing with unusual clarity: for these three companies, the distance between a Washington decision and a cash flow line is short. BrightSpring's US$14.4 billion, Clover's US$2.5 billion and agilon's US$5.9 billion all sit downstream of federal payment rules. What remains unknown is which lever moves first and how fast. The screen frames that as opportunity; the honest reading is that it is concentrated risk, measurable from public documents, that rewards readers who follow the machinery rather than the headlines.
